Provided by Tiger Fintech (Singapore) Pte. Ltd.

Keros Therapeutics, Inc.

14.44
-0.0300-0.21%
Post-market: 14.440.00000.00%18:26 EDT
Volume:351.44K
Turnover:5.08M
Market Cap:586.49M
PE:132.53
High:14.60
Open:14.36
Low:14.34
Close:14.47
Loading ...

Keros Therapeutics Inc - to Reduce Headcount by About 45%

THOMSON REUTERS
·
29 May

BRIEF-ADAR1 Capital Management - ISS Recommends Withholding Votes From Keros Therapeutics Directors Mary Ann Gray & Alpna Seth At Annual Meeting

Reuters
·
21 May

ADAR1 announces advisor recommendation to Keros stockholders to withhold votes

TIPRANKS
·
21 May

Adar1 Capital Management - Iss Recommends Withholding Votes From Keros Therapeutics Directors Mary Ann Gray & Alpna Seth at Annual Meeting

THOMSON REUTERS
·
21 May

ISS Recommends Keros Therapeutics Shareholders Withhold Votes from Directors Ahead of Annual Meeting

Reuters
·
21 May

BRIEF-Keros Therapeutics Board Undertaking Formal Review Process To Evaluate Strategic Alternatives

Reuters
·
19 May

Keros Therapeutics Inc - Board Undertaking Formal Review Process to Evaluate Strategic Alternatives

THOMSON REUTERS
·
19 May

Press Release: Keros Therapeutics Highlights Commitment to Maximizing Stockholder Value

Dow Jones
·
19 May

ADAR1 Capital Management Advises Withholding Votes for Keros Therapeutics Directors Ahead of June Shareholder Meeting

Reuters
·
13 May

BRIEF-Keros Therapeutics Strategic Committee Intends To Consider A Comprehensive Range Of Strategic Alternatives

Reuters
·
09 May

Keros Therapeutics: Strategic Committee Intends to Consider a Comprehensive Range of Strategic Alternatives

THOMSON REUTERS
·
09 May

Keros Therapeutics: Board Continues to Recommend Stockholders Vote "for" Its 3 Director Nominees

THOMSON REUTERS
·
09 May

Keros Therapeutics Shareholder ADAR1 Capital to Withhold Votes for Two Board Members

Dow Jones
·
09 May

Keros Therapeutics Stockholder ADAR1 Seeks Business Restructuring Alleging Prolonged Underperformance

MT Newswires Live
·
09 May

BRIEF-ADAR1 Capital Management Calls For Keros Therapeutics To Restructure Business, Reduce Headcount

Reuters
·
09 May

Adar1 Capital Management: Urged Keros to Discontinue Development of Ker-012 and Ker-065

THOMSON REUTERS
·
09 May

Adar1 Capital Management: to "Withhold" Votes on Re-Election of Mary Ann Gray & Alpna Seth at Keros Therapeutics' Annual Meeting of Stockholders

THOMSON REUTERS
·
09 May

Adar1 Capital Management: Calls for Keros to Restructure Business, Significantly Reduce Headcount, Return Excess Capital to Stockholders

THOMSON REUTERS
·
09 May

ADAR1 Capital Management Urges Keros Therapeutics Shareholders to Withhold Votes for Directors Ahead of June 2025 Meeting

Reuters
·
09 May

Keros Therapeutics Reports Strong Q1 2025 Results

TIPRANKS
·
08 May